Minerva Capital Research Solutions

Nifty Pharma stocks

The Nifty Pharma tracks India's largest listed drug makers, many of which earn much of their sales from generic medicines sold abroad.

28,371.8+0.61%

Close on 19 Nov 2026 · 20 member stocks (list as of 20 Nov 2026)

1M
+10.8%
3M
+7.4%
6M
+14%
YTD
+24.9%
1Y
+24.8%
3Y
+79.5%
5Y
+110.5%
10Y
+166.6%

Price returns: index level only, dividends not included.

Today in the Nifty Pharma

Prices at 03:29 pm IST, 20 Nov

11 up, 9 down

16 of 20 trade above their 200-day average.

None near a 52-week high.

"Near" = within 1% of the highest or lowest price of the last year. Price moves only, not advice.

What's new in Nifty Pharma companies

Notable exchange filings, credit rating actions and fund raises of the last 30 days, newest first.

  • 18 Nov 2026FilingAlkem LaboratoriesMedium impactPositive

    Strong Q2 with 13.8% sales growth and 22.5% margin, but full-year margins to stay flat as new MedTech and biotech businesses drag.

    Source
  • 16 Nov 2026FilingGlenmark PharmaceuticalsMedium impactPositive

    Glenmark launched authorized generic Inlyta in the US targeting a $538.4m brand market.

    Source
  • 13 Nov 2026FilingDivi's LaboratoriesHigh impactVery positive

    Superb Q2 with 32% sales and 64% profit growth guides to sustained double-digit growth and major peptide-led capex.

    Source
  • 13 Nov 2026Credit ratingSai Life SciencesUpgrade

    India Ratings upgraded Sai Life Sciences: IND AA; IND A1+ (was IND AA-; IND A1+)

    India Ratings upgraded Sai Life to AA Stable on strong growth and margins despite Rs 1100-1300 cr capex.

    Source
  • 12 Nov 2026FilingGland PharmaHigh impactVery positive

    Strong 21% H1 growth with 28% margins and 15% full-year guidance plus Rs 1000 cr new capacity backs sustained double-digit profitable growth.

    Source
  • 12 Nov 2026FilingAlkem LaboratoriesMedium impactNeutral

    Strong 13.8% Q2 revenue growth plus Occlutech MedTech buy offset by higher new-regime tax and Biotech losses cutting PAT.

    Source
  • 12 Nov 2026FilingSai Life SciencesMedium impactPositive

    Strong Q2 (+23%) with H2 guided stronger and Bidar expansion ready supports ~20% revenue growth amid heavy capex.

    Source
  • 11 Nov 2026FilingBioconMedium impactPositive

    Soft Q2 with 5% sales spilling to Q3, but double-digit H2 growth, $500m new contracts and lower interest point to stronger earnings.

    Source

Nifty Pharma in numbers

Worked out from the member companies' latest results and today's market value. Our own sums, so they can differ a little from the figures NSE publishes.

P/E
41.5x
Market value ÷ profit
P/B
5.7x
Market value ÷ book
Dividend yield
0.5%
Weighted by size
Median ROE
16%
Return on equity
Sales growth
+22.7%
Median, vs a year ago
Profit growth
−0.2%
Median, vs a year ago

Results for the Sep 2026 quarter

19 of 20 companies have reported. Profit grew at 9 and sales at 16 of them, against the same quarter a year earlier.

Largest members by market value

  1. Sun Pharmaceutical Industries20.3% of the total
  2. Divi's Laboratories13.7% of the total
  3. Torrent Pharmaceuticals8% of the total
  4. Laurus Labs5.9% of the total
  5. Zydus Lifesciences5.4% of the total

Total market value ₹ 22,18,476 Cr.. P/E covers the 20 members with a profit and a market value. Shares of the total are by full market value, not NSE's free-float weights.

Nifty Pharma against other indices

Each line starts at 100, so you can read who gained more over the same time.

  • Nifty Pharma+25%
  • Nifty 50−2.6%

Index levels only, dividends not included. Weekly closes beyond one year.

All 20 stocks

Changes to the Nifty Pharma

No changes since we began tracking this list on 20 Nov 2026. NSE reviews its indices twice a year, with changes usually taking effect at the end of March and September; they will show here.